Lucatumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lucatumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target CD40
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Molar mass 146 kg/mol
 NYesY (what is this?)  (verify)

Lucatumumab (CHIR 12.12 or HCD122)[1] is a human monoclonal antibody against CD40[2] development of which was discontinued by Novartis in 2013 after it was investigated for the treatment of various types of cancer like multiple myeloma and follicular lymphoma.[3]

It is an antagonist to CD40 that was created by scientists at Chiron using Abgenix' XenoMouse transgenic mouse to generate fully human antibodies.[4][5] It was made part of the collaboration between Chiron and Xoma that the companies commenced in 2004.[6][7][8] Novartis took over the project when it acquired Chiron in 2005.[9][10]

In in vitro studies, it inhibited cell proliferation induced by CD40 ligands and induced cell lysis.[11]

Over three Phase 1 trials in multiple myeloma and chronic lymphocytic leukemia, the companies made an effort to determine the optimal dose, and obtained unclear results.[1] The Phase I part of a planned Phase I/II trial in multiple myeloma was started in 2005, and in 2012 was updated to Phase II and closed; as of 2014 the results had not been published.[1]

References[edit]

  1. ^ a b c Hassan, SB; Sørensen, JF; Olsen, BN; Pedersen, AE (April 2014). "Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.". Immunopharmacology and immunotoxicology. 36 (2): 96–104. PMID 24555495. doi:10.3109/08923973.2014.890626. 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
  3. ^ "Lucatumumab". AdisInsight. Retrieved 20 February 2017. 
  4. ^ "Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference". XOMA and Chiron vis Businesswire. December 2, 2004. 
  5. ^ Weng, Wen-Kai; Tong, Xia; Luqman, Mohammad; Levy, Ronald (16 November 2004). "(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin’s Lymphoma.". Blood. 104 (11): 3279–3279. ISSN 0006-4971. 
  6. ^ "Chiron and Xoma in MAb deal - Pharmaceutical industry news". The Pharma Letter. March 8, 2004. . Part of Xoma's 10-K filed 2004-03-15. Index page at SEC Edgar.
  7. ^ "Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA". Xoma via SEC Edgar. 
  8. ^ "Exhibit 10.2 Amended Research, Development and Commercialization Agreement". www.sec.gov. Xoma via SEC Edgar. May 26, 2005. 
  9. ^ Tansey, Bernadette (November 1, 2005). "Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion". San Francisco Chronicle. 
  10. ^ "Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)". Xoma. November 10, 2008. 
  11. ^ "NCI Drug Dictionary: lucatumumab". National Cancer Institute. Retrieved 20 February 2017.